RxDoctor Payments DataLook up a doctor →

Nenita Bala-Albano, MD

Internal Medicine · Waipahu, HINPI 1336301944

Payments from drug & device makers

$10,518in general payments, 2019–2025

Across 442 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Bayer$873
  • Novo Nordisk$784
  • Teva Pharmaceuticals USA, Inc.$746
  • Neurocrine Biosciences, Inc.$669
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,518 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$10,610
Medicare patients
24
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol54$79,531
JardianceEmpagliflozin58$64,205
LinzessLinaclotide68$62,226
OzempicSemaglutide14$33,981
KerendiaFinerenone18$30,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,735
EliquisApixaban19$19,069
VascepaIcosapent Ethyl14$11,617
Atorvastatin Calcium324$6,746
SymbicortBudesonide/Formoterol Fumarate11$5,659
Rosuvastatin Calcium188$4,432
Losartan Potassium160$2,558
Amlodipine Besylate249$2,518
Risedronate Sodium13$1,765
Tamsulosin Hcl77$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$605$85,19065 claims
Boehringer IngelheimJardiance$59$64,20558 claims
AbbVieLinzess$1,714$62,22668 claims
Novo NordiskOzempic$784$33,98114 claims
BayerKerendia$873$30,07218 claims
GSKTrelegy Ellipta$90$20,73530 claims
PfizerEliquis$198$19,06919 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$123$1,099106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Waipahu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →